Objectives: This meta-analysis investigated the impact of renin-angiotensin-aldosterone system (RAAS) blockade on the occurrence of contrast-induced nephropathy (CIN). Methods: Twelve studies comparing the use of RAAS blockade in a total of 4,493 patients undergoing a contrast-using procedure were included. The primary endpoint was the overall postprocedural incidence of CIN. Results: In the overall pooled analysis, there was no significant difference between the two groups, RAAS blockade ‘used' versus ‘not-used', in the incidence of postprocedural CIN in the random-effects model (OR 1.27, 95% CI 1.77-2.11, p = 0.351, I2 = 61.9%). In the stratified analysis, however, for chronic RAAS blockade users, the continuation of the drug was significantly associated with a higher incidence of CIN compared with discontinuation (OR 2.06, 95% CI 1.62-2.61, p < 0.001, I2 = 0.0%). A hazard of continuation was marked in a subgroup of older patients or in patients with chronic kidney disease. For drug-na9ve patients, however, administration of RAAS blockade before contrast procedures did not reduce the development of CIN significantly (OR 0.52, 95% CI 0.23-1.16, p = 0.108, I2 = 34.2%). Conclusion: Discontinuation of RAAS blockade in chronic users is associated with a significantly lower incidence of CIN, whereas administration of RAAS blockade as a preventive measure for na9ve patients did not show a significant effect on the incidence of CIN. i 2014 S. Karger AG, Basel

1.
Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK: Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51:521-526.
2.
Duan SB, Zhou XR, Pemg YM, Liu FY, Zhuo L, Li J, Chen YY, Xia YC: Prevention of radiocontrast-media-induced nephrotoxicity by perindopril and amlodipine in humans. China J Mod Med 2003;13:32-36.
3.
Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL: The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography (in Turkish). Anadolu Kardiyol Derg 2003;3:98-103.
4.
Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL: The effect of captopril on contrast-induced nephropathy in diabetic patients. Kidney Blood Press Res 2004;27 411.
5.
Hashemi M, Kharazi A, Shahidi S: Captopril for prevention of contrast-induced nephropathy in patients undergoing coronary angioplasty: a double-blind placebo controlled clinical trial. J Res Med Sci 2005;10:305-308.
6.
Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E: Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006;104:c20-c27.
7.
Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H: Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or at-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant 2010;25:759-764.
8.
Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, Lee HH, Chung W, Jung JY: The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. Am J Kidney Dis 2012;60:576-582.
9.
Baris N, Ozpelit E, Dogan NB, Kangul H, Gul S, Akdeniz B, Guneri S: The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients. Anadolu Kardiyol Derg 2013;13:245-250.
10.
Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF: The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008;40:749-755.
11.
Li XM, Cong HL, Li TT, He LJ, Zhou YJ: Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention. Chin Med J 2011;124:2101-2106.
12.
Shemirani H, Pourrmoghaddas M: A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention. Saudi J Kidney Dis Transplant 2012;23:280-285.
13.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
14.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
15.
McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-1428.
16.
Li X, Li T, Fu N, Hu Y, Cong H: Is angiotensin-converting enzyme inhibitor appropriate for contrast-induced nephropathy? A meta-analysis about this field. Int J Cardiol 2012;155:486-488.
17.
Li X, Li T, Cong H: Is angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis? A review about its paradox. Cardiovasc Ther 2012;30:273-276.
18.
Patel K, King CA, Jovin IS: Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med 2011;12:90-93.
19.
Onuigbo MA: Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin Prac 2011;118:c407-c419.
20.
Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013;346:e8525.
21.
Ahmed AK, Kamath NS, El Kossi M, El Nahas AM: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010;25:3977-3982.
22.
Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH: Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005;67:1684-1691.
23.
Suissa S, Hutchinson T, Brophy JM, Kezouh A: Ace-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006;69:913-919.
24.
Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein FH, Rosen S: Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988;82:401-412.
25.
Brewster UC, Perazella MA: The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-272.
26.
Fleming I, Kohlstedt K, Busse R: New fACEs to the renin-angiotensin system. Physiology (Bethesda) 2005;20:91-95.
27.
Munzel T, Keaney JF Jr: Are ACE inhibitors a ‘magic bullet' against oxidative stress? Circulation 2001;104:1571-1574.
28.
Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80:282-287.
29.
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS: Renal considerations in angiotensin-converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985-1991.
30.
Lee HT, Kim M, Kim J, Kim N, Emala CW: TGF-F1 release by volatile anesthetics mediates protection against renal proximal tubule cell necrosis. Am J Nephrol 2007;27:416-424.
31.
Junaid A, Rosenberg ME, Hostetter TH: Interaction of angiotensin II and TGF-F1 in the rat remnant kidney. J Am Soc Nephrol 1997;8:1732-1738.
32.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 2013;82:E1-E27.
33.
Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D: Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-2555.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.